Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3.

Dupont C, Chen Y, Xu Z, Roquet-Banères F, Blaise M, Witt AK, Dubar F, Biot C, Guérardel Y, Maurer FP, Chng SS, Kremer L.

J Biol Chem. 2019 Sep 27. pii: jbc.RA119.010135. doi: 10.1074/jbc.RA119.010135. [Epub ahead of print]

2.

OGT Controls the Expression and the Glycosylation of E-cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines.

Biwi J, Clarisse C, Biot C, Kozak RP, Madunic K, Mortuaire M, Wuhrer M, Spencer DIR, Schulz C, Guerardel Y, Lefebvre T, Vercoutter-Edouart AS.

Proteomics. 2019 Nov;19(21-22):e1800452. doi: 10.1002/pmic.201800452. Epub 2019 Aug 20.

PMID:
31373757
3.

Three-Dimensional Correlative Imaging of a Malaria-Infected Cell with a Hard X-ray Nanoprobe.

Yang Y, Fus F, Pacureanu A, da Silva JC, De Nolf W, Biot C, Bohic S, Cloetens P.

Anal Chem. 2019 May 21;91(10):6549-6554. doi: 10.1021/acs.analchem.8b05957. Epub 2019 May 10.

PMID:
31026149
4.

Novel Zebrafish Mono-α2,8-sialyltransferase (ST8Sia VIII): An Evolutionary Perspective of α2,8-Sialylation.

Chang LY, Teppa E, Noel M, Gilormini PA, Decloquement M, Lion C, Biot C, Mir AM, Cogez V, Delannoy P, Khoo KH, Petit D, Guérardel Y, Harduin-Lepers A.

Int J Mol Sci. 2019 Jan 31;20(3). pii: E622. doi: 10.3390/ijms20030622.

5.

GORAB scaffolds COPI at the trans-Golgi for efficient enzyme recycling and correct protein glycosylation.

Witkos TM, Chan WL, Joensuu M, Rhiel M, Pallister E, Thomas-Oates J, Mould AP, Mironov AA, Biot C, Guerardel Y, Morelle W, Ungar D, Wieland FT, Jokitalo E, Tassabehji M, Kornak U, Lowe M.

Nat Commun. 2019 Jan 10;10(1):127. doi: 10.1038/s41467-018-08044-6.

6.

The Many Ways by Which O-GlcNAcylation May Orchestrate the Diversity of Complex Glycosylations.

Biwi J, Biot C, Guerardel Y, Vercoutter-Edouart AS, Lefebvre T.

Molecules. 2018 Nov 2;23(11). pii: E2858. doi: 10.3390/molecules23112858. Review.

7.

Asking more from metabolic oligosaccharide engineering.

Gilormini PA, Batt AR, Pratt MR, Biot C.

Chem Sci. 2018 Sep 18;9(39):7585-7595. doi: 10.1039/c8sc02241k. eCollection 2018 Oct 21. Review.

8.

One, Two, Three: A Bioorthogonal Triple Labelling Strategy for Studying the Dynamics of Plant Cell Wall Formation In Vivo.

Simon C, Lion C, Spriet C, Baldacci-Cresp F, Hawkins S, Biot C.

Angew Chem Int Ed Engl. 2018 Dec 17;57(51):16665-16671. doi: 10.1002/anie.201808493. Epub 2018 Nov 21.

PMID:
30370981
9.

MicroPlate Sialyltransferase Assay: A Rapid and Sensitive Assay Based on an Unnatural Sialic Acid Donor and Bioorthogonal Chemistry.

Noel M, Gilormini PA, Cogez V, Lion C, Biot C, Harduin-Lepers A, Guérardel Y.

Bioconjug Chem. 2018 Oct 17;29(10):3377-3384. doi: 10.1021/acs.bioconjchem.8b00529. Epub 2018 Sep 20.

PMID:
30192128
10.

Integrating glycomics and genomics uncovers SLC10A7 as essential factor for bone mineralization by regulating post-Golgi protein transport and glycosylation.

Ashikov A, Abu Bakar N, Wen XY, Niemeijer M, Rodrigues Pinto Osorio G, Brand-Arzamendi K, Hasadsri L, Hansikova H, Raymond K, Vicogne D, Ondruskova N, Simon MEH, Pfundt R, Timal S, Beumers R, Biot C, Smeets R, Kersten M, Huijben K; CDG group, Linders PTA, van den Bogaart G, van Hijum SAFT, Rodenburg R, van den Heuvel LP, van Spronsen F, Honzik T, Foulquier F, van Scherpenzeel M, Lefeber DJ; CDG group, Mirjam W, Han B, Helen M, Helen M, Peter VH, Jiddeke VK, Diego M, Lars M, Katja BH, Jozef H, Majid A, Kevin C, Johann TWN.

Hum Mol Genet. 2018 Sep 1;27(17):3029-3045. doi: 10.1093/hmg/ddy213.

PMID:
29878199
11.

Chemical glycomics enrichment: imaging the recycling of sialic acid in living cells.

Gilormini PA, Lion C, Vicogne D, Guérardel Y, Foulquier F, Biot C.

J Inherit Metab Dis. 2018 May;41(3):515-523. doi: 10.1007/s10545-017-0118-3. Epub 2018 Jan 2.

12.

Ferroquine, the next generation antimalarial drug, has antitumor activity.

Kondratskyi A, Kondratska K, Vanden Abeele F, Gordienko D, Dubois C, Toillon RA, Slomianny C, Lemière S, Delcourt P, Dewailly E, Skryma R, Biot C, Prevarskaya N.

Sci Rep. 2017 Nov 21;7(1):15896. doi: 10.1038/s41598-017-16154-2.

13.

BLISS: Shining a light on lignification in plants.

Simon C, Lion C, Huss B, Blervacq AS, Spriet C, Guérardel Y, Biot C, Hawkins S.

Plant Signal Behav. 2017 Aug 3;12(8):e1359366. doi: 10.1080/15592324.2017.1359366. Epub 2017 Aug 8.

14.

Probing the CMP-Sialic Acid Donor Specificity of Two Human β-d-Galactoside Sialyltransferases (ST3Gal I and ST6Gal I) Selectively Acting on O- and N-Glycosylproteins.

Noel M, Gilormini PA, Cogez V, Yamakawa N, Vicogne D, Lion C, Biot C, Guérardel Y, Harduin-Lepers A.

Chembiochem. 2017 Jul 4;18(13):1251-1259. doi: 10.1002/cbic.201700024. Epub 2017 May 22.

15.

BLISS: A Bioorthogonal Dual-Labeling Strategy to Unravel Lignification Dynamics in Plants.

Lion C, Simon C, Huss B, Blervacq AS, Tirot L, Toybou D, Spriet C, Slomianny C, Guerardel Y, Hawkins S, Biot C.

Cell Chem Biol. 2017 Mar 16;24(3):326-338. doi: 10.1016/j.chembiol.2017.02.009. Epub 2017 Mar 2.

16.

1H-1,2,3-triazole-tethered uracil-ferrocene and uracil-ferrocenylchalcone conjugates: Synthesis and antitubercular evaluation.

Singh A, Biot C, Viljoen A, Dupont C, Kremer L, Kumar K, Kumar V.

Chem Biol Drug Des. 2017 Jun;89(6):856-861. doi: 10.1111/cbdd.12908. Epub 2016 Nov 29.

PMID:
27860285
17.

Improved workflow for the efficient preparation of ready to use CMP-activated sialic acids.

Gilormini PA, Lion C, Noel M, Krzewinski-Recchi MA, Harduin-Lepers A, Guérardel Y, Biot C.

Glycobiology. 2016 Nov;26(11):1151-1156. doi: 10.1093/glycob/cww084. Epub 2016 Aug 19.

PMID:
27543325
18.

A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus.

Dupont C, Viljoen A, Dubar F, Blaise M, Bernut A, Pawlik A, Bouchier C, Brosch R, Guérardel Y, Lelièvre J, Ballell L, Herrmann JL, Biot C, Kremer L.

Mol Microbiol. 2016 Aug;101(3):515-29. doi: 10.1111/mmi.13406. Epub 2016 Jun 1.

19.

A sequential bioorthogonal dual strategy: ManNAl and SiaNAl as distinct tools to unravel sialic acid metabolic pathways.

Gilormini PA, Lion C, Vicogne D, Levade T, Potelle S, Mariller C, Guérardel Y, Biot C, Foulquier F.

Chem Commun (Camb). 2016 Feb 7;52(11):2318-21. doi: 10.1039/c5cc08838k.

PMID:
26727964
20.

Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii.

Martins-Duarte ES, Dubar F, Lawton P, da Silva CF, Soeiro Mde N, de Souza W, Biot C, Vommaro RC.

PLoS One. 2015 May 7;10(5):e0125705. doi: 10.1371/journal.pone.0125705. eCollection 2015.

21.

New heterocyclic compounds: Synthesis and antitrypanosomal properties.

Pomel S, Dubar F, Forge D, Loiseau PM, Biot C.

Bioorg Med Chem. 2015 Aug 15;23(16):5168-74. doi: 10.1016/j.bmc.2015.03.029. Epub 2015 Mar 20.

PMID:
25835356
22.

Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.

Dervaux B, Baseilhac E, Fagon JY; participants of round table n4 of Giens XXIX : Biot Claire 4 Blachier Corinne 5 Braun Eric 6 Debrou, Biot C, Blachier C, Braun E, Debroucker F, Detournay B, Ferretti C, Granger M, Jouan-Flahault C, Lussier MD, Meyer A, Muller S, Pigeon M, De Sahb R, Sannié T, Sapède C, Vray M.

Therapie. 2014 Jul-Aug;69(4):323-8. doi: 10.2515/therapie/2014048. Epub 2014 Aug 12. English, French.

PMID:
25230355
23.

In vitro and in vivo antischistosomal activity of ferroquine derivatives.

Keiser J, Vargas M, Rubbiani R, Gasser G, Biot C.

Parasit Vectors. 2014 Sep 4;7:424. doi: 10.1186/1756-3305-7-424.

24.

Ferroquine as an oxidative shock antimalarial.

Dive D, Biot C.

Curr Top Med Chem. 2014;14(14):1684-92.

PMID:
25116581
25.

Évaluation médico-économique des produits de santé. Méthodologie pour la définition d'un impact significatif sur les dépenses de l'Assurance maladie et choix des référentiels pour l'interprétation des résultats.

Dervaux B, Baseilhac E, Fagon JY; et les participants à la table ronde N°4 de Giens XXIX :, Biot C, Blachier C, Braun E, Debroucker F, Detournay B, Ferretti C, Granger M, Jouan-Flahault C, Lussier MD, Meyer A, Muller S, Pigeon M, De Sahb R, Sannié T, Sapède C, Vray M.

Therapie. 2014 Jul-Aug;69(4):323-30. doi: 10.2515/therapie/2014046. French. No abstract available.

PMID:
27393226
26.

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN.

Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.

PMID:
24674149
27.

7-chloroquinoline-isatin conjugates: antimalarial, antitubercular, and cytotoxic evaluation.

Raj R, Biot C, Carrère-Kremer S, Kremer L, Guérardel Y, Gut J, Rosenthal PJ, Forge D, Kumar V.

Chem Biol Drug Des. 2014 May;83(5):622-9. doi: 10.1111/cbdd.12273. Epub 2014 Mar 14.

PMID:
24341638
28.

Assessing ER and Golgi N-glycosylation process using metabolic labeling in mammalian cultured cells.

Péanne R, Vanbeselaere J, Vicogne D, Mir AM, Biot C, Matthijs G, Guérardel Y, Foulquier F.

Methods Cell Biol. 2013;118:157-76. doi: 10.1016/B978-0-12-417164-0.00010-0.

PMID:
24295306
29.

Alkynyl monosaccharide analogues as a tool for evaluating Golgi glycosylation efficiency: application to Congenital Disorders of Glycosylation (CDG).

Vanbeselaere J, Vicogne D, Matthijs G, Biot C, Foulquier F, Guerardel Y.

Chem Commun (Camb). 2013 Dec 14;49(96):11293-5. doi: 10.1039/c3cc45914d. Epub 2013 Oct 24.

PMID:
24153356
30.

4-Aminoquinoline-β-lactam conjugates: synthesis, antimalarial, and antitubercular evaluation.

Raj R, Biot C, Carrère-Kremer S, Kremer L, Guérardel Y, Gut J, Rosenthal PJ, Kumar V.

Chem Biol Drug Des. 2014 Feb;83(2):191-7. doi: 10.1111/cbdd.12225. Epub 2013 Oct 28.

PMID:
24034147
31.

The ferroquine antimalarial conundrum: redox activation and reinvasion inhibition.

Dubar F, Slomianny C, Khalife J, Dive D, Kalamou H, Guérardel Y, Grellier P, Biot C.

Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7690-3. doi: 10.1002/anie.201303690. Epub 2013 Jun 13.

PMID:
23765846
32.

α-L-fucosidase inhibition by pyrrolidine-ferrocene hybrids: rationalization of ligand-binding properties by structural studies.

Hottin A, Wright DW, Steenackers A, Delannoy P, Dubar F, Biot C, Davies GJ, Behr JB.

Chemistry. 2013 Jul 15;19(29):9526-33. doi: 10.1002/chem.201301001. Epub 2013 Jun 5.

PMID:
23740878
33.

[From cannabis to selective CB2R agonists: molecules with numerous therapeutical virtues].

Leleu-Chavain N, Biot C, Chavatte P, Millet R.

Med Sci (Paris). 2013 May;29(5):523-8. doi: 10.1051/medsci/2013295016. Epub 2013 May 28. French.

34.

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R.

PLoS One. 2013;8(2):e56327. doi: 10.1371/journal.pone.0056327. Epub 2013 Feb 25.

35.

The antimalarial ferroquine is an inhibitor of hepatitis C virus.

Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, Wychowski C, Biot C, Dubuisson J.

Hepatology. 2013 Jul;58(1):86-97. doi: 10.1002/hep.26273. Epub 2013 May 14.

PMID:
23348596
36.

Medicinal potential of ciprofloxacin and its derivatives.

Castro W, Navarro M, Biot C.

Future Med Chem. 2013 Jan;5(1):81-96. doi: 10.4155/fmc.12.181. Review.

PMID:
23256815
37.

Antiprotozoal activity of ferroquine.

Pomel S, Biot C, Bories C, Loiseau PM.

Parasitol Res. 2013 Feb;112(2):665-9. doi: 10.1007/s00436-012-3183-4. Epub 2012 Nov 15.

PMID:
23229318
38.

Azide-alkyne cycloaddition en route towards 1H-1,2,3-triazole-tethered β-lactam-ferrocene and β-lactam-ferrocenylchalcone conjugates: synthesis and in vitro anti-tubercular evaluation.

Kumar K, Carrère-Kremer S, Kremer L, Guérardel Y, Biot C, Kumar V.

Dalton Trans. 2013 Feb 7;42(5):1492-500. doi: 10.1039/c2dt32148c. Epub 2012 Oct 29.

PMID:
23108229
39.

Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Breban R, Bisiaux A, Biot C, Rentsch C, Bousso P, Albert ML.

Oncoimmunology. 2012 Jan 1;1(1):9-17.

40.

Iminosugar-ferrocene conjugates as potential anticancer agents.

Hottin A, Dubar F, Steenackers A, Delannoy P, Biot C, Behr JB.

Org Biomol Chem. 2012 Aug 7;10(29):5592-7. doi: 10.1039/c2ob25727k. Epub 2012 Jun 20.

PMID:
22717621
41.

Opening up the advantages of the ruthenocenic bioprobes of ferroquine: distribution and localization in Plasmodium falciparum-infected erythrocytes.

Biot C, Dubar F, Khalife J, Slomianny C.

Metallomics. 2012 Aug;4(8):780-3. doi: 10.1039/c2mt20063e. Epub 2012 Jun 15.

PMID:
22700030
42.

Deciphering the Resistance-Counteracting Functions of Ferroquine in Plasmodium falciparum-Infected Erythrocytes.

Dubar F, Bohic S, Dive D, Guérardel Y, Cloetens P, Khalife J, Biot C.

ACS Med Chem Lett. 2012 Apr 13;3(6):480-3. doi: 10.1021/ml300062q. eCollection 2012 Jun 14.

43.

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML.

Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.

44.

Statistical methodology for the detection of small changes in distances by EXAFS: application to the antimalarial ruthenoquine.

Curis E, Dubar F, Nicolis I, Bénazeth S, Biot C.

J Phys Chem A. 2012 Jun 14;116(23):5577-85. doi: 10.1021/jp301811r. Epub 2012 May 31.

PMID:
22607521
45.

The apicoplast: a key target to cure malaria.

MacRae JI, Maréchal E, Biot C, Botté CY.

Curr Pharm Des. 2012;18(24):3490-504. Review.

PMID:
22607142
46.

Ferrocene-based antimalarials.

Roux C, Biot C.

Future Med Chem. 2012 Apr;4(6):783-97. doi: 10.4155/fmc.12.26. Review.

PMID:
22530641
47.

Synthesis and in vitro anti-tubercular evaluation of 1,2,3-triazole tethered β-lactam-ferrocene and β-lactam-ferrocenylchalcone chimeric scaffolds.

Kumar K, Singh P, Kremer L, Guérardel Y, Biot C, Kumar V.

Dalton Trans. 2012 May 21;41(19):5778-81. doi: 10.1039/c2dt30514c. Epub 2012 Apr 3.

PMID:
22473422
48.

Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.

Supan C, Mombo-Ngoma G, Dal-Bianco MP, Ospina Salazar CL, Issifou S, Mazuir F, Filali-Ansary A, Biot C, Ter-Minassian D, Ramharter M, Kremsner PG, Lell B.

Antimicrob Agents Chemother. 2012 Jun;56(6):3165-73. doi: 10.1128/AAC.05359-11. Epub 2012 Mar 19.

49.

[Targeting malaria parasite at the level of apicoplast: an update].

Biot C, Botté CY, Dubar F, Maréchal E.

Med Sci (Paris). 2012 Feb;28(2):163-71. doi: 10.1051/medsci/2012282014. Epub 2012 Feb 27. Review. French.

50.

The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of action.

Biot C, Castro W, Botté CY, Navarro M.

Dalton Trans. 2012 Jun 7;41(21):6335-49. doi: 10.1039/c2dt12247b. Epub 2012 Feb 24. Review.

PMID:
22362072

Supplemental Content

Support Center